The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-β production or aggregation have failed in Phase III clinical testing, and many others are in various stages of development. Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pathogenetic studies have shown that Aβ peptide accumulation in the brain is an early and central event, 2”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [2]
In the citing paper
“One possible resolution is that amyloid pathology acts only as a trigger in sporadic AD (Karran et al., 2011); i.e., Aβ accumulation is necessary but insufficient to cause full-blown disease.”
From The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques (2019) · cites this paper as Karran et al., 2011
In the citing paper
“since it is known that the Aβ plaques act as a driver of AD pathology63 and the accumulation Aβ plaques in the brain initiates a complex multicellular neurodegenerative process.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [63]
In the citing paper
“The amyloid cascade hypothesis, which dominated the field for over three decades, proposed that the abnormal accumulation of Aβ initiates a downstream cascade leading to tau hyperphosphorylation, synaptic dysfunction, and neuronal death [6, 7].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [7]
In the citing paper
“a possible cause of clinical failure could be the difficulty of inhibiting these proteinases without causing side effects resulting from non-targeted proteolytic inhibition on their many physiological substrates”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Karran et al., 2011
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“The apolipoprotein E ( APOE ) gene represents the major genetic risk factor for A”
BackgroundAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“The discovery that AD could be inherited in an autosomal dominant fashio”
Background
Research works printed but not linked: 2
- Burns, A. & Ilife, S. Dementia. BMJ 338, 405–409 (2009).
- Alzheimer, A. About a peculiar disease of the cerebral cortex. [in German] Centralblatt für Nervenheilkunde Psychiatrie 30, 177–179 (1907).
Cited by
Items 301–400 of 1,007
Alzheimer's disease: The amyloid hypothesis on trial
Harrison, J. R., & Owen, M. J. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.167569 · Cited by 96
Anti-Viral Properties of Amyloid-β Peptides
Bourgade, K., Dupuis, G., Frost, E. H., & Fülöp, T. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160517 · Cited by 96
“Despite extensive efforts documented by more than 116,854 references to AD currently archived in PubMed® and 7,076 references to its prevention at the moment of writing, there is still no efficient treatment to halt progression of the disease, let alone a cure for it [17–19].”
Astroglia in Alzheimer’s Disease
Verkhratsky, A., Parpura, V., Rodriguez, J. J., & Zorec, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9913-8_11 · Cited by 102
P‐glycoprotein: a role in the export of amyloid‐β in Alzheimer's disease?
Chai, A. B., Leung, G. K. F., Callaghan, R., & Gelissen, I. C. (2020) · The FEBS Journal · doi:10.1111/febs.15148 · Cited by 96
Biomarkers for Alzheimer Disease: Classical and Novel Candidates’ Review
Kadmiri, N. E., Said, N., Slassi, I., Moutawakil, B. E., & Nadifi, S. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.07.017 · Cited by 102
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing
Fang, J., Pieper, A. A., Nussinov, R., Lee, G., Bekris, L., Leverenz, J. B., Cummings, J., & Cheng, F. (2020) · Medicinal Research Reviews · doi:10.1002/med.21709 · Cited by 94
“γ‐secretases via two pathways (non‐amyloidogenic and amyloidogenic), which produce distinct peptides.(62,63) In the non‐ amyloidogenic pathway, proteolysis of APP by α‐ and γ‐secretases yields nonpathogenic fragments, including sAPPα.”
BackgroundBoccardi, M., Altomare, D., Ferrari, C., Festari, C., Guerra, U. P., Paghera, B., Pizzocaro, C., Lussignoli, G., Geroldi, C., Zanetti, O., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3751 · Cited by 94
“Treatment Plan At all time points, physicians reported medication prescription as follows: (1) acetylcholinesterase inhibitors; (2) memantine hydrochloride; (3) anxiolytics, hypnotics, or antidepressants; and (4) antipsychotics or anticonvulsants.”
MethodWang, T., Liu, X.-H., Guan, J., Ge, S., Wu, M.-B., Lin, J.-P., & Yang, L.-R. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.076 · Cited by 93
Liu, L., Wan, W., Xia, S., Kalionis, B., & Li, Y. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.05.004 · Cited by 107
One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug
Hughes, R. E., Nikolic, K., & Ramsay, R. R. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00177 · Cited by 93
“The amyloid hypothesis that the generation of toxic A β from amyloid precursor protein (APP) and A β aggregation result in the pathophysiological changes associated with AD ( Figure 1 ) led to compounds targeting A β (Karran et al., 2011; Eisele et al., 2015).”
BackgroundParthsarathy, V., McClean, P. L., Hölscher, C., Taylor, M., Tinker, C. L., Jones, G., Kolosov, O., Salvati, E., Gregori, M., Masserini, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054769 · Cited by 115
“There is substantial and well known evidence from molecular genetics, transgenic animal studies and aggregation/toxicity studies to suggest that the conversion of the b-amyloid (Ab) peptide from monomers into aggregated forms in the brain is a key (and possibly seminal) event in the pathogenesis of AD [3], [4].”
BackgroundBACE inhibitors in clinical development for the treatment of Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Sardone, R., Piccininni, C., Dibello, V., Stallone, R., Giannelli, G., Bellomo, A., Greco, A., et al. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1531706 · Cited by 92
Chung, Y. J., Kim, K., Lee, B. I., & Park, C. B. (2017) · Small · doi:10.1002/smll.201700983 · Cited by 97
Miniature microscopes for large-scale imaging of neuronal activity in freely behaving rodents
Ziv, Y., & Ghosh, K. K. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.04.001 · Cited by 100
Vojtechova, I., Machacek, T., Kristofikova, Z., Stuchlik, A., & Petrasek, T. (2022) · PLOS Pathogens · doi:10.1371/journal.ppat.1010929 · Cited by 92
“The amyloid cascade hypothesis supposes that the deposition of Aβ peptide in the brain is the main cause of AD pathology [29,30].”
BackgroundThe Alzheimer's Amyloid-Degrading Peptidase, Neprilysin: Can We Control It?
Nalivaeva, N. N., Belyaev, N. D., Zhuravin, I. A., & Turner, A. J. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/383796 · Cited by 92
“trials of inhibitors preventing Aβ formation [6].”
Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures
Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91
Cebers, G., Alexander, R. C., Haeberlein, S. B., Han, D., Goldwater, R., Ereshefsky, L., Olsson, T., Ye, N., Rosen, L., Russell, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160701 · Cited by 91
“Consequently, investigating potential disease modifi-cation through modulation of A (cid:2) concentrations has become one of the highest priority therapeutic targets in Alzheimer’s disease [4, 7].”
ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer’s disease
Wang, B.-J., Her, G. M., Hu, M.-K., Chen, Y.-W., Tung, Y.-T., Wu, P.-Y., Hsu, W.-M., Lee, H., Jin, L.-W., Hwang, S.-P. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618804114 · Cited by 91
Zilberter, M., Ivanov, A., Ziyatdinova, S., Mukhtarov, M., Malkov, A., Alpár, A., Tortoriello, G., Botting, C. H., Fülöp, L., Osypov, A. A., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12127 · Cited by 91
“It posits that accumulation of amyloid-b peptide (Ab) in the brain results in neuronal dysfunction, synaptic loss, and cognitive decline in AD (Karran et al. 2011; Selkoe 2011).”
BackgroundHellwig, S., Masuch, A., Nestel, S., Katzmarski, N., Meyer-Luehmann, M., & Biber, K. (2015) · Scientific Reports · doi:10.1038/srep14624 · Cited by 91
Zhang, Z., Li, X.-G., Wang, Z.-H., Song, M., Yu, S. P., Kang, S. S., Liu, X., Zhang, Z., Xie, M., Liu, G.-P., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-018-0286-z · Cited by 89
Copper imbalance in Alzheimer’s disease: Convergence of the chemistry and the clinic
Kepp, K. P., & Squitti, R. (2019) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2019.06.018 · Cited by 96
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
“Despite the scientific strength of the amyloid hypothesis, to date clinical trials targeting Aβ have failed to clearly demonstrate clinical benefit [14, 36] with the consequence that the amyloid hypothesis has been questioned [7, 40, 41].”
BackgroundCornejo, A., Sandoval, F. A. A., Caballero, L., Machuca, L., Muñoz, P., Caballero, J., Perry, G. L., Ardiles, A., Areche, C., & Melo, F. S. M. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1347783 · Cited by 96
Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights
Villa, C., Lavitrano, M., Salvatore, E., & Combi, R. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030061 · Cited by 89
“Aβ plaques are composed of various Aβ peptides, including the 40 and 42 amino acid products (Aβ40 and Aβ42), generated as a result of the sequential proteolytic cleavage of Aβ precursor protein (APP) by β-site APP-cleaving enzyme 1 (BACE-1) and the γ-secretase complex [4].”
BackgroundThe missing link in the amyloid cascade of Alzheimer’s disease – Metal ions
Tiiman, A., Palumaa, P., & Tõugu, V. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.023 · Cited by 104
“the period of 6–7 years is included in the plaques (Karran et al., 2011).”
Emerging Therapeutics for Alzheimer's Disease
Chiang, K., & Koo, E. H. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135932 · Cited by 88
Bisecting GlcNAc modification stabilizes BACE1 protein under oxidative stress conditions
Kizuka, Y., Nakano, M., Kitazume, S., Saito, T., Saido, T. C., & Taniguchi, N. (2016) · Biochemical Journal · doi:10.1042/bj20150607 · Cited by 85
García-González, L., Pilat, D., Baranger, K., & Rivera, S. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00244 · Cited by 88
“In the case of therapies based on β- and γ-secretase inhibitors, a possible cause of clinical failure could be the difficulty of inhibiting these proteinases without causing side effects resulting from non-targeted proteolytic inhibition on their many physiological substrates (Karran et al., 2011; Vassar et al., 2014;…”
BackgroundYang, S.-H., Li, W., Sumien, N., Forster, M. J., Simpkins, J. W., & Liu, R. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.005 · Cited by 94
“All therapeutics purported to decrease amyloid-b plague have failed to demonstrate any efficacy in clinical trials (Karran and Hardy, 2014; Karran et al., 2011).”
BackgroundCCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer’s disease
Cherry, J. D., Stein, T. D., Tripodis, Y., Alvarez, V. E., Huber, B. R., Au, R., Kiernan, P. T., Daneshvar, D. H., Mez, J., Solomon, T. M., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0185541 · Cited by 87
Soluble TREM2 changes during the clinical course of Alzheimer’s disease: A meta-analysis
Liu, D., Cao, B., Zhao, Y., Huang, H., McIntyre, R. S., Rosenblat, J. D., & Zhou, H. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.08.038 · Cited by 87
Callens, M., Kraskovskaya, N., Derevtsova, K. Z., Annaert, W. G., Bultynck, G., Борисович, Б. И., & Vervliet, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.118997 · Cited by 92
Targeting the Prodromal Stage of Alzheimer's Disease: Bioenergetic and Mitochondrial Opportunities
Caldwell, C. C., Yao, J., & Brinton, R. D. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0324-8 · Cited by 94
Py, N. A., Bonnet, A. E., Bernard, A., Marchalant, Y., Charrat, E., Checler, F., Khrestchatisky, M., Baranger, K., & Rivera, S. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00247 · Cited by 76
“Histopathologically, AD is characterized by the accumulation of intracellular and extracellular deposits of amyloid beta peptide (Aβ), which according to the amyloid cascade hypothesis is considered as a crucial process in AD pathogenesis (Hardy and Higgins, 1992; Karran et al., 2011).”
BackgroundBrody, A. H., & Strittmatter, S. M. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.09.007 · Cited by 86
Kim, D. K., Han, D., Park, J., Choi, H., Park, J.-C., Cha, M.-Y., Woo, J., Byun, M. S., Lee, D. Y., Kim, Y., et al. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0326-z · Cited by 85
Agostinho, P., Pliássova, A., Oliveira, C. R., & Cunha, R. A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142730 · Cited by 85
“However, it is widely recognized that autosomal mutations in PS1 or PS2 genes are one of the possible causes for familial AD [14].”
BackgroundKell, D. B., & Pretorius, E. (2016) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2016.08.006 · Cited by 96
The role of regulatory T cells in nervous system pathologies
Duffy, S. S., Keating, B. A., Perera, C. J., & Moalem‐Taylor, G. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24073 · Cited by 96
Alzheimer's disease: a mathematical model for onset and progression
Bertsch, M., Franchi, B., Marcello, N., Tesi, M. C., & Tosin, A. (2017) · PORTO Publications Open Repository TOrino (Politecnico di Torino) · Cited by 87
Mangold, S. L., O’Leary, D. J., & Grubbs, R. H. (2014) · Journal of the American Chemical Society · doi:10.1021/ja507166g · Cited by 91
Alzheimer’s disease: as it was in the beginning
Kozlov, S. O., Afonin, A. М., Evsyukov, I., & Бондаренко, А. Б. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0006 · Cited by 95
Pitt, J., Wilcox, K. C., Tortelli, V., Diniz, L. P., Oliveira, M. S., Dobbins, C., Yu, X.-W., Nandamuri, S., Gomes, F. C. A., DiNunno, N., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-06-0416 · Cited by 84
“There has been considerable controversy regarding the involvement of Aβ-derived toxins in AD pathogenesis (Karran et al., 2011).”
BackgroundHou, T., Yang, H., Wang, W., Wu, Q., Tian, Y., & Jia, J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171110 · Cited by 88
“Abnormal A (cid:2) aggregation was originally shown to contribute to a series of pathological changes in AD [2].”
Agwa, M. M., Abdelmonsif, D. A., Khattab, S. N., & Sabra, S. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.058 · Cited by 82
Nanomaterials toward the treatment of Alzheimer’s disease: Recent advances and future trends
Zeng, H., Qi, Y., Zhang, Z., Liu, C., Peng, W., & Zhang, Y. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.01.014 · Cited by 83
Uddin, M. S., Al Mamun, A., Kabir, M. T., Ashraf, G. M., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02116-9 · Cited by 86
Risk factor SORL1: from genetic association to functional validation in Alzheimer’s disease
Andersen, O. M., Rudolph, I.-M., & Willnow, T. E. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1615-4 · Cited by 83
“These mutations are typically associated with an overall increase in the production of Aβ or with a shift towards generation of the more disease-prone variant Aβ42 [45].”
BackgroundPetrov, A. M., Lam, M., Mast, N., Moon, J., Li, Y., Maxfield, E., & Pikuleva, I. A. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00737-0 · Cited by 86
Duan, Y., Lu, L., Chen, J., Wu, C., Liang, J., Zheng, Y., Wu, J., Rong, P., & Tang, C. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0864-6 · Cited by 96
scyllo-Inositol, Preclinical, and Clinical Data for Alzheimer’s Disease
Ma, K., Thomason, L. A. M., & McLaurin, J. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00006-4 · Cited by 94
Greve, H. J., Dunbar, A. L., Lombo, C. G., Ahmed, C., Thang, M., Messenger, E. J., Mumaw, C. L., Johnson, J. A., Kodavanti, U. P., Oblak, A. L., et al. (2023) · Brain · doi:10.1093/brain/awac113 · Cited by 82
Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?
Mahgoub, N., & Alexopoulos, G. S. (2016) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.12.003 · Cited by 81
“Brain accumulation of Aβ amyloid is part of the cascade leading to AD (58).”
Capurro, V., Busquet, P., Lopes, J. P., Bertorelli, R., Tarozzo, G., Bolognesi, M. L., Piomelli, D., Reggiani, A., & Cavalli, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056870 · Cited by 80
“However, to date, no innovative candidates have successfully gone through phase III clinical trials, mainly owing to lack of efficacy or the emergence of toxicity issues [5].”
BackgroundTen Challenges of the Amyloid Hypothesis of Alzheimer’s Disease
Kepp, K. P. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160550 · Cited by 81
“…to imply that not the total A (cid:2) levels, but the ratio between long and short forms of A (cid:2) (mostly A (cid:2) 42 /A (cid:2) 40 ) are molecular determinants of disease [29, 71]; A (cid:2) 42 is well-established to be more toxic than A (cid:2) 40 [6, 9], so this argument had support.”
Lomont, J. P., Ostrander, J. S., Ho, J.-J., Petti, M. K., & Zanni, M. T. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b06826 · Cited by 82
Esmaeili, M. H., Bahari, B., & Salari, A. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.01.001 · Cited by 85
Zhou, X., Jiang, L., Fan, G., Yang, H., Wu, L., Huang, Y., Xu, N., & Li, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.03.037 · Cited by 86
Bhat, B. A., Almilaibary, A., Mir, R. A., Aljarallah, B. M., Mir, W. R., Ahmad, F., & Mir, M. A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.884345 · Cited by 93
Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid Cascade
Potter, H., & Wisniewski, T. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/489428 · Cited by 81
“…Aurora, CO 80045, USA 3 Departments of Neurology, Pathology, and Psychiatry, New York University School of Medicine, New York, NY 10016, USA Correspondence should be addressed to Huntington Potter, hpotter@health.usf.edu Received 16 December 2011; Accepted 23 April 2012 Academic Editor:…”
BackgroundInfluentialYu, D., Guan, Y., Bai, F., Du, Z., Gao, N., Ren, J., & Qu, X. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201805835 · Cited by 81
Platelets and Alzheimer’s disease: Potential of APP as a biomarker
Evin, G. (2012) · World Journal of Psychiatry · doi:10.5498/wjp.v2.i6.102 · Cited by 80
Rombouts, F. J. R., Tresadern, G., Delgado, Ó., Martínez‐Lamenca, C., Gool, M. V., García-Molina, A., de Diego, S. A. A., Oehlrich, D., Prokopcová, H., Alonso, J. M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01101 · Cited by 84
Benitez, D. P., Jiang, S., Wood, J., Wang, R., Hall, C. M., Peerboom, C., Wong, N., Stringer, K. M., Vitanova, K. S., Smith, V. C., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00457-0 · Cited by 78
“In particular, overexpression of APP results in not only raised Aβ but also other APP metabolites, the levels of which may not be increased to any substantial degree in Alzheimer’s disease [3].”
BackgroundInfluentialSelf-citationBen-Menachem-Zidon, O., Ben-Menahem, Y., Ben-Hur, T., & Yirmiya, R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.208 · Cited by 87
“Although the formation of amyloid plaques represents the hallmark pathological symptom of AD, the relationship between plaques and cognitive functioning is still intensely debated (Golde et al, 2011; Karran et al, 2011).”
BackgroundMechanism of amyloid β−protein dimerization determined using single−molecule AFM force spectroscopy
Lv, Z., Roychaudhuri, R., Condron, M. M., Teplow, D. B., & Lyubchenko, Y. L. (2013) · Scientific Reports · doi:10.1038/srep02880 · Cited by 84
Multitarget Strategies in Alzheimer’S Disease: Benefits and Challenges on the Road to Therapeutics
Rosini, M., Simoni, E., Caporaso, R., & Minarini, A. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0003 · Cited by 88
Akhoon, B. A., Pandey, S., Tiwari, S., & Pandey, R. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.03.004 · Cited by 81
Veloso, A. J., Chow, A. M., Ganesh, H. V. S., Li, N., Dhar, D., Wu, D. C. H., Mikhaylichenko, S. N., Brown, I. R., & Kerman, K. (2014) · Analytical Chemistry · doi:10.1021/ac500424t · Cited by 89
Ting, K. K., Coleman, P., Kim, H. J., Zhao, Y., Mulangala, J., Cheng, N. C., Li, W., Gunatilake, D., Johnstone, D. M., Loo, L., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00927-x · Cited by 76
“The failure of clinical trials of Aβ-clearing therapeutics to impact on AD progression and cognitive outcome has called into question the amyloid hypothesis as central for AD [3] or that delivery of these therapies have been too late in the disease progression or at efficacious concentrations [4].”
BackgroundEhrnhoefer, D. E., Wong, B. K. Y., & Hayden, M. R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3556 · Cited by 77
Henderson, S. J., Andersson, C., Narwal, R., Janson, J., Goldschmidt, T. J., Appelkvist, P., Bogstedt, A., Steffen, A.-C., Haupts, U., Tebbe, J., et al. (2014) · Brain · doi:10.1093/brain/awt308 · Cited by 77
“The amyloid cascade hypothesis suggests that one of the main causes of the pathology of Alzheimer’s disease is the accumulation of amyloid-b within the brain leading to synaptic dysfunction and neuronal loss (Hardy and Higgins, 1992; Hardy and Selkoe, 2002; Karran et al., 2011; Schenk et al., 2012).”
BackgroundProtective effects of linalool against amyloid beta-induced cognitive deficits and damages in mice
Xu, P., Wang, K., Lü, C., Dong, L., Gao, L., Yan, M., Aibai, S., Yang, Y., & Liu, X. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.02.010 · Cited by 84
A disease with a sweet tooth: exploring the Warburg effect in Alzheimer’s disease
Atlante, A., Lidia de, B. A. R. I., Bobba, A., & Amadoro, G. (2017) · Biogerontology · doi:10.1007/s10522-017-9692-x · Cited by 80
“According to the ‘amyloid hypothesis’, the Ab, a 4-kDa peptide generated by specific proteolytic cleavage of amyloid precursor protein (APP), initiates the pathological alterations in tau metabolism which, in turn, further support and reinforce the apoptotic cell death culminating with the neuronal loss (Karran et al.…”
BackgroundVascular pathology: Cause or effect in Alzheimer disease?
Rius-Pérez, S., Tormos, A. M., Pérez, S., & Taléns-Visconti, R. (2018) · Neurología (English Edition) · doi:10.1016/j.nrleng.2015.07.008 · Cited by 75
Sasahara, K., Morigaki, K., & Shinya, K. (2013) · Physical Chemistry Chemical Physics · doi:10.1039/c3cp44517h · Cited by 89
Studying micro RNA Function and Dysfunction in Alzheimer’s Disease
Lukiw, W. J., Andreeva, T. V., Grigorenko, A. P., & Rogaev, E. I. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2012.00327 · Cited by 76
“Currently, there are no adequate preventive or curative treatments for this leading cause of senile dementia, and pharmacological strategies and treatments directed at AD symptoms, and specifically targeted to neurotransmitter deficits, amyloidogenesis, and the progressively inflammatory nature of this brain degenerat…”
BackgroundRogers, K., Felsenstein, K. M., Hrdlicka, L., Tu, Z., Albayya, F., Lee, W., Hopp, S., Miller, M.-J., Spaulding, D., Yang, Z., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-61 · Cited by 75
“Aβ42 was significantly lowered in both the TBS soluble and formic acid extractable fractions (TBS, F[2,12] = 12.”
BackgroundInfluentialClark, I. A., Atwood, C., Bowen, R. L., Paz-Filho, G., & Vissel, B. (2012) · Pharmacological Reviews · doi:10.1124/pr.112.005850 · Cited by 80
“…when amyloid was confirmed to have been reduced (Holmes et al., 2008; Green et al., 2009; Salloway et al., 2009; Extance, 2010), has led to much reassessment and repositioning that has led to lucid arguments for nonfailure of the amyloid model itself (Karran et al., 2011; Sperling et al., 2011).”
BackgroundNew evolutions in the BACE1 inhibitor field from 2014 to 2018
Hsiao, C.-C., Rombouts, F., & Gijsen, H. J. M. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.049 · Cited by 74
Wang, X., Zhang, M., & Liu, H. (2019) · Bioscience, Biotechnology, and Biochemistry · doi:10.1080/09168451.2018.1562874 · Cited by 74
“Evidence suggested that accumulation of βamyloid peptide (Aβ) in the brain gives rise to the onset of AD [10,11].”
BackgroundGarabadu, D., & Verma, J. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.04.006 · Cited by 75
Melatonin as a mitochondrial protector in neurodegenerative diseases
Wongprayoon, P., & Govitrapong, P. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2614-x · Cited by 80
“An imbalance between Aβ production and degradation leads to the accumulation of abnormal proteins that are highly toxic to the neuronal cells [101, 102].”
BackgroundYu, W., Jin, H., & Huang, Y. (2021) · Clinical Science · doi:10.1042/cs20200844 · Cited by 81
Valensin, D., Gabbiani, C., & Messori, L. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.04.010 · Cited by 84
Lukiw, W. J. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.672559 · Cited by 81
“Notably, the membrane depicted in this drawing may be that of the endoplasmic reticulum, Golgi apparatus or neuronal plasma membrane, so amyloidogenic cleavage of bAPP into Ab40 or Ab42 peptides may culminate in either intracellular or extracellular Ab peptide evolution with ensuing neurotoxic events in that compartme…”
BackgroundCalcium signalling: A common target in neurological disorders and neurogenesis
Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.12.002 · Cited by 79
Neuronally derived extracellular vesicles: an emerging tool for understanding Alzheimer’s disease
Watson, L. S., Hamlett, E. D., Stone, T. D., & Sims-Robinson, C. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0317-5 · Cited by 74
Molecular Genetics of Neurodegenerative Dementias
Hinz, F. I., & Geschwind, D. H. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a023705 · Cited by 73
“The finding that all three causative genes are involved in the production of Ab peptides led to the “amyloid cascase hypothesis” (Hardy and Higgins 1992; reviewed in Karran et al. 2011).”
BackgroundAngarica, V. E., Ventura, S., & Sancho, J. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-316 · Cited by 82
“Background The formation of intracellular amyloid fibrils is a widespread phenomenon in eukaryotes [1-4] and it has been found related to a number of beneficial adaptive cellular functions [5-11], to protein-encoded heritable information transmission in yeast [12-15], and to a variety of important diseases in mammals…”
BackgroundWang, X., Perumalsamy, H., Kwon, H. W., Na, Y., & Ahn, Y. (2015) · Scientific Reports · doi:10.1038/srep16127 · Cited by 80
Li, M.-Z., Ji, J.-G., Zheng, L.-J., Shen, J., Li, X.-Y., Zhang, Q., Bai, X., & Wang, Q.-S. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.239449 · Cited by 72
“…no increase in amyloid beta (Aβ) production in sporadic AD, but that a deficiency in Aβ clearance is usually accompanied by age-related lysosomal dysfunction (LaFerla et al., 2007; Nixon, 2007; Nixon et al., 2008; Karran et al., 2011), which is considered to be the initiating factor of the disease.”
BackgroundYan, L., Xie, Y., Satyanarayanan, S. K., Zeng, H., Liu, Q., Huang, M., Ma, Y., Wan, J., Yao, X., Su, K., et al. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.05.033 · Cited by 79
Mann, C. N., Devi, S. S., Kersting, C. T., Bleem, A. V., Karch, C. M., Holtzman, D. M., & Gallardo, G. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm4107 · Cited by 73
“Although there is much clarity needed before fully understanding the relationship between A and tau, it appears that A pathophysiological effects occur early in AD development, which seems necessary but not sufficient for priming vulnerable brain regions for the intrusion of tau pathology [reviewed in (3, 4)].”
BackgroundZuhl, A. M., Nolan, C. E., Brodney, M. A., Niessen, S., Atchison, K., Houle, C., Karanian, D. A., Ambroise, C., Brulet, J. W., Beck, E. M., et al. (2016) · Nature Communications · doi:10.1038/ncomms13042 · Cited by 73
“The amyloid cascade hypothesis of Alzheimer’s disease (AD) links disease pathology to an accumulation of cerebral amyloid beta (A b ) 6 .”
Sales, T. A., Prandi, I. G., de Castro, A. A., Leal, D. H. S., da Cunha, E. F. F., Kuča, K., & Ramalho, T. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081829 · Cited by 75
“Faced with the existence of other molecular targets directly or indirectly involved in AD, it opens up a range of possibilities for remediation and therapies [43,60].”
BackgroundLipopolysaccharide endotoxemia induces amyloid-β and p-tau formation in the rat brain.
Wang, L., Wu, Q., Kirk, R. A., Horn, K. P., Salem, A. E., Hoffman, J. M., Yap, J. T., Sonnen, J. A., Towner, R. A., Bozza, F. A., et al. (2018) · Europe PMC (PubMed Central) · Cited by 109
Feng, H., Wang, C., He, W., Wu, X.-J., Li, S., Zeng, Z., Wei, M., & He, B. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-018-0374-4 · Cited by 72
Metadata
- Authors
- Karran, E., Mercken, M., & Strooper, B. D.
- Affiliations
- Janssen (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Corresponding author
- Karran, Eric
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-19
- Volume
- 10
- Issue
- 9
- Pages
- 698-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2079749054
- Cited by
- 2,188
- References
- 157
- Citations by year
- 2026: 74 · 2025: 115 · 2024: 130 · 2023: 139 · 2022: 141 · 2021: 158 · 2020: 174 · 2019: 191 · 2018: 174 · 2017: 163 · 2016: 171 · 2015: 160 · 2014: 151 · 2013: 130 · 2012: 107
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid hypothesis, Alzheimer's disease, amyloid-beta, amyloid-beta aggregation, amyloid-beta production, clinical trial design, phase III trial failure, drug development
- MeSH terms
- Alzheimer Disease, Animals, Brain Chemistry, Humans, Research Design, Amyloid beta-Peptides, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Age of Onset, Disease Progression, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.